And ALK-04, a compound synthesized by in silico screening using the X-ray crystal structure of ALKBH5, was identified as a specific ALKBH5 inhibitor that improved the efficacy of cancer immunotherapy for patients with melanoma [109]. This evidence concerns the gene ALKBH5 and melanoma.